ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Additionally, we examined the impact of ponatinib (AP24534), a pan-BCR-ABL kinase inhibitor approved for treating chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia.